Following the fate of nanocarriers for improved drug therapy

To address the limitations of current nanomedicine in translational patway, we aim to gain a deeper insight on the essential interaction between nanocarriers and biological environment as the first step in optimization of final formulation for intravenous administration. By convincingly predicting the nanoparticle fate already at in vitro stage of formulation development, we expected that the disappointment of suboptimal in vivo outcome could be avoided, allowing better translation from laboratory to clinic. To achieve this goal we aim to follow the fate of nanocarriers in simulated biological environment applying state-of-the-art methodologies that permit close follow up of nanocarriers, their interactions with cells, stability in biological environment leading to final in vivo proof-of-concept.